UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1098-14
Program Prior Authorization/Notification
Medication Stivarga® (regorafenib)
P&T Approval Date 11/2012, 4/2013, 7/2013, 11/2014, 11/2015, 6/2016, 6/2017, 6/2018,
6/2019, 6/2020, 6/2021, 6/2022, 6/2023, 6/2024, 6/2025
Effective Date 9/1/2025
1. Background:
Stivarga (regorafenib) is a kinase inhibitor indicated for the treatment of patients with: metastatic
colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-
and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR
therapy; locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who
have been previously treated with imatinib mesylate (Gleevec) and sunitinib malate (Sutent);
hepatocellular carcinoma (HCC) who have been previously treated with Nexavar (sorafenib
tosylate).1
The National Cancer Comprehensive Network (NCCN) also recommends additional use of
Stivarga in colon cancer, rectal cancer, soft tissue sarcoma, hepatocellular carcinoma, biliary tract
cancer, bone cancer, gastrointestinal stromal tumor (GIST), and glioblastoma.2
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of
19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the
notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Stivarga will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Colorectal Cancer (CRC)
1. Initial Therapy
a. Stivarga will be approved based on all of the following criteria:
(1) Diagnosis of advanced or metastatic colorectal cancer
© 2025 UnitedHealthcare Services, Inc.
1
-AND-
(2) History of failure, contraindication, or intolerance to treatment with all of the
following:
(a) Oxaliplatin-based chemotherapy
(b) Irinotecan-based chemotherapy
(c) Anti-VEGF-based chemotherapy
-AND-
(3) One of the following:
(a) Tumor is RAS mutant-type
-OR-
(b) Both of the following:
i. Tumor is RAS wild-type
ii. History of failure, contraindication, or intolerance to anti-EGFR therapy
[e.g., Erbitux (cetuximab), Vectibix (panitumumab)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Stivarga will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Stivarga therapy
Authorization will be issued for 12 months.
C. Soft Tissue Sarcoma (STS)
1. Initial Therapy
a. Stivarga will be approved based on both of the following criteria:
(1) Diagnosis of soft tissue sarcoma
-AND-
(2) One of the following
(a) Extremity/superficial trunk or head/neck that is non-adipocytic with
advanced/metastatic disease with disseminated metastases
(b) Retroperitoneal/intra-abdominal that is non-adipocytic with recurrent
unresectable or stage IV disease
© 2025 UnitedHealthcare Services, Inc.
2
(c) Advanced/metastatic pleomorphic rhabdomyosarcoma
(d) Angiosarcoma
Authorization will be issued for 12 months.
2. Reauthorization
a. Stivarga will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Stivarga therapy
Authorization will be issued for 12 months.
D. Gastrointestinal Stromal Tumor (GIST)
1. Initial Therapy
a. Stivarga will be approved based on all of the following criteria:
(1) Diagnosis of gastrointestinal stromal tumor (GIST)
-AND-
(2) Disease is one of the following:
(a) Gross residual (R2 resection)
(b) Unresectable primary
(c) Tumor rupture
(d) Recurrent/metastatic
-AND-
(3) One of the following:
(a) SDH-deficient GIST
-OR-
(b) History of disease progression on both of the following:
i. Imatinib mesylate (Gleevec)
ii. One of the following
• Sutent (sunitinib malate)
• Qinlock (ripretinib)
Authorization will be issued for 12 months.
2. Reauthorization
© 2025 UnitedHealthcare Services, Inc.
3
a. Stivarga will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Stivarga therapy
Authorization will be issued for 12 months.
E. Hepatobiliary Cancers
1. Initial Therapy
a. Stivarga will be approved based on one of the following criteria:
(1) Both of the following:
(a) Diagnosis of one of the following:
i. Gallbladder cancer
ii. Extrahepatic cholangiocarcinoma
iii. Intrahepatic cholangiocarcinoma
-AND-
(b) Disease is one of the following:
i. Unresectable
ii. Gross residual (R2)
iii. Metastatic
-OR-
(2) Both of the following:
(a) Diagnosis of hepatocellular carcinoma
-AND-
(b) Used as subsequent-line therapy for disease progression
Authorization will be issued for 12 months.
2. Reauthorization
a. Stivarga will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Stivarga therapy
Authorization will be issued for 12 months.
F. Bone Cancer
© 2025 UnitedHealthcare Services, Inc.
4
1. Initial Therapy
a. Stivarga will be approved based on both of the following criteria:
(1) Diagnosis of one of the following bone cancer:
(a) Dedifferentiated chondrosarcoma
(b) Ewing Sarcoma
(c) High grade undifferentiated pleomorphic sarcoma (UPS)
(d) Mesenchymal chondrosarcoma
(e) Osteosarcoma
(f) Other primary round cell tumors of the bone (e.g., CIC::DUX4,
BCOR::CCNB3)
-AND-
(2) Used as second-line therapy
Authorization will be issued for 12 months.
2. Reauthorization
a. Stivarga will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Stivarga therapy
Authorization will be issued for 12 months.
G. Glioblastoma
1. Initial Therapy
a. Stivarga will be approved based on the following criterion:
(1) Diagnosis of recurrent or progressive glioblastoma
Authorization will be issued for 12 months.
2. Reauthorization
a. Stivarga will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Stivarga therapy
Authorization will be issued for 12 months.
H. Uterine Sarcoma
1. Initial Therapy
© 2025 UnitedHealthcare Services, Inc.
5
a. Stivarga will be approved based on all of the following criteria:
(1) Diagnosis of uterine sarcoma
-AND-
(2) Disease is one of the following:
(a) Advanced
(b) Recurrent/metastatic
(c) Inoperable
-AND-
(3) Used as second-line or subsequent therapy
Authorization will be issued for 12 months.
2. Reauthorization
a. Stivarga will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Stivarga therapy
Authorization will be issued for 12 months.
I. NCCN Recommended Regimens
a. The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a
Category of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Stivarga [package insert]. Whippany, NJ: Bayer Healthcare Pharmaceuticals, Inc. February 2025.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
https://www.nccn.org/professionals/drug_compendium/content/. Accessed April 28, 2025.
© 2025 UnitedHealthcare Services, Inc.
6
Program Prior Authorization/Notification – Stivarga (regorafenib)
Change Control
9/2014 Administrative change – Tried/Failed exemption for State of New
Jersey removed.
11/2014 Annual review. Removed VEGF criteria from colorectal cancer and
added disease progression. Added progressive to GIST. Updated
background & references.
11/2015 Annual review. Revised CRC and GIST criteria. Increased
authorization from 3 months to 12 month. Updated references.
6/2016 Annual review. Revised CRC criteria, removing KRAS/NRAS mutant
requirement. Updated references.
6/2017 Annual review. Updated coverage criteria to include hepatocellular
cancer to align with updated package insert. Updated background,
formatting and references.
6/2018 Annual review. Updated references.
6/2019 Annual review. Updated criteria for colorectal cancer and soft tissue
sarcoma based on NCCN guidelines. Updated references.
6/2020 Annual review. Updated criteria for hepatobiliary carcinoma according
to NCCN guidelines. Addition of osteosarcoma and glioblastoma
according to NCCN. Updated references.
6/2021 Annual review. Updated criteria for soft tissue sarcoma in accordance
with NCCN. Updated references.
6/2022 Annual review. Revised criteria to remove indication for solitary
fibrous tumor in accordance with NCCN. Updated references.
6/2023 Annual review. Updated background to include SDH-deficient GIST.
Updated STS criteria. Updated hepatobiliary cancers criteria. Updated
glioblastoma criteria. Updated references. Added state mandate
footnote.
6/2024 Annual review. Added examples to anti-EGFR therapy. Removed
“criteria” from all reauthorization sections. Separated gastrointestinal
stromal tumor criteria from soft tissue sarcoma criteria and updated
criteria per NCCN guideline. Added disease subtype criteria to
hepatobiliary cancer section. Changed osteosarcoma section to bone
cancer and added Ewing Sarcoma to criteria per NCCN guideline.
Updated background and reference.
6/2025 Annual review. Added new indication and coverage criteria for uterine
sarcoma. Updated coverage criteria for colorectal cancer,
gastrointestinal stromal tumors, and bone cancer based on NCCN.
Updated references.
© 2025 UnitedHealthcare Services, Inc.
7